BPS Bioscience
![]() |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BPS offers one of the largest selections of unique recombinant proteins and assay kits for epigenetic studies, immune checkpoints, metabolism and cell signaling pathways to improve human health.
Cloning and Expression: BPS Bioscience's Molecular Biology Services team can help you achieve any molecular biology research goal you are trying to achieve. Our gene cloning and site-directed mutagenesis services are often the first step in custom protein expression, analytic development, and custom cell line development projects.
Purification and Protein Modification: Choose BPS Bioscience for your protein, reduction, purification and modification needs. Using our cloning and expression services, the constructs can be optimized for high purity, high performance protein expression. We are also specialized in protein labeling to provide improved products for high quality testing.
Cell line development: Let our experts help you reduce time and complexity with our stable cell line development services. We produce customized cell lines for protein production and compound screening. Our specialty in reporter assays for immune control pathways offers great opportunities for research on co-immunotherapies.
Test Development and Screening Services: Evaluate key compounds with our biochemical and cell screening services. Save time by allowing us to filter your compounds of interest against our unique test panels or to determine IC50 values with our portfolio of hundreds of tests so you can focus on advancing your discovery program of drugs.
Learn more :
Watch the video :
Website: bpsbioscience.com
|
![SARS-CoV-2 - Antigens (proteins and peptides) for research and development](https://www.clinisciences.com/en/upload/thumbs/sars-cov-2-antigen-ws23rw-ba30d3.jpg)
SARS-CoV-2 - Antigens (proteins and peptides) for research and development
The newly identified coronavirus, SARS-CoV-2 (2019-nCoV), has led to pneumonia (COVID-19). SARS-CoV-2 belongs to the Betacoronavirus Genus, which also includes SARS CoV (2003) and MERS CoV (2012). Same as all other coronaviruses, the genome of SARS-CoV-2 (2019-nCoV) encodes the spike protein, the envelope protein, the membrane protein, and the nucleocapsid protein.
The spike protein (S-protein) mediates receptor binding and membrane fusion. Spike protein contains two subunits, S1 and S2. S1 contains a receptor binding domain (RBD), which is responsible for recognizing and binding with the cell surface receptor. S2 subunit is the "stem" of the structure, which contains other basic elements needed for the membrane fusion. The spike protein is the common target for neutralizing antibodies and vaccines. It's been reported that SARS-CoV-2 (2019-nCoV) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. Indeed, the recombinant Spike protein can bind with recombinant ACE2 protein.
The Nucleocapsid Protein (N-protein) is the most abundant protein in coronavirus. The N-protein is a highly immunogenic phosphoprotein, and it is normally very conserved. The N protein of coronavirus is often used as a marker in diagnostic assays.
To aid the efforts of developing diagnostic kits, vaccines and neutralizing antibodies against this virus, we offer a panel of research reagents for SARS-CoV-2, including recombinant antigens (the N protein, S protein, the S1 and S2 subunits of the S protein, and the RBD domain of the S proteins).
![](/upload/covid-19-qkujcp.jpg)